Trials / Unknown
UnknownNCT03129139
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Minneamrita Therapeutics LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
Conditions
- Advanced Cancer
- Gastric Cancer
- Breast Cancer
- Pancreatic Cancer
- Prostate Cancer Metastatic
- Colo-rectal Cancer
- Solid Tumor
- Solid Carcinoma
- Solid Carcinoma of Stomach
- Cancer of Stomach
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Minnelide™Capsules | Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor. |
Timeline
- Start date
- 2017-10-10
- Primary completion
- 2024-06-01
- Completion
- 2024-12-01
- First posted
- 2017-04-26
- Last updated
- 2023-10-18
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03129139. Inclusion in this directory is not an endorsement.